(Q54217812)

English

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Middle East respiratory syndrome coronavirus

0 references

0 references

1 reference

based on heuristic

inferred from title

Middle East respiratory syndrome

1 reference

based on heuristic

inferred from title

author name string

Seo-Yeon Jung

1

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Kyung Won Kang

2

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Eun-Young Lee

3

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Dong-Won Seo

4

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hong-Lim Kim

5

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hak Kim

6

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

TaeWoo Kwon

7

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hye-Lim Park

8

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Hun Kim

9

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Sang-Myeong Lee

10

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Jae-Hwan Nam

11

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

language of work or name

0 references

publication date

5 May 2018

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS-like disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Dipeptidyl Peptidase 4 Distribution in the Human Respiratory Tract: Implications for the Middle East Respiratory Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Coronaviruses - drug discovery and therapeutic options.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

MERS-CoV spike protein: Targets for vaccines and therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Immunogenicity of an adenoviral-based Middle East Respiratory Syndrome coronavirus vaccine in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Systemic and mucosal immunity in mice elicited by a single immunization with human adenovirus type 5 or 41 vector-based vaccines carrying the spike protein of Middle East respiratory syndrome coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Protective Efficacy of Recombinant Modified Vaccinia Virus Ankara Delivering Middle East Respiratory Syndrome Coronavirus Spike Glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

A truncated receptor-binding domain of MERS-CoV spike protein potently inhibits MERS-CoV infection and induces strong neutralizing antibody responses: implication for developing therapeutics and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Receptor-binding domain-based subunit vaccines against MERS-CoV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

MERS-CoV spike nanoparticles protect mice from MERS-CoV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

A synthetic consensus anti-spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Evaluation of candidate vaccine approaches for MERS-CoV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Peptide vaccines against cancer, infectious diseases, and conception

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Rapid generation of a mouse model for Middle East respiratory syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

The paradigm of Th1 and Th2 cytokines: its relevance to autoimmunity and allergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

CD8+ T cell responses following replication-defective adenovirus serotype 5 immunization are dependent on CD11c+ dendritic cells but show redundancy in their requirement of TLR and nucleotide-binding oligomerization domain-like receptor signaling

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenoviral vector immunity: its implications and circumvention strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Adenovirus vector-induced immune responses in nonhuman primates: responses to prime boost regimens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Cellular immune responses of healthy individuals to intradermal administration of an E1-E3- adenovirus gene transfer vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Redox-active protein thioredoxin prevents proinflammatory cytokine- or bleomycin-induced lung injury.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Combined virus-like particle and fusion protein-encoding DNA vaccination of cotton rats induces protection against respiratory syncytial virus without causing vaccine-enhanced disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

RSV vaccine-enhanced disease is orchestrated by the combined actions of distinct CD4 T cell subsets

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2018.04.082

7 January 2021

Poly (lactic-glycolic) acid copolymer encapsulation of recombinant adenovirus reduces immunogenicity in vivo

1 reference

https://pubmed.ncbi.nlm.nih.gov/29739720

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.VACCINE.2018.04.082

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 May 2018

http://europepmc.org/abstract/MED/29739720

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54217812&oldid=1711423338"